1. Autoimmune thyroiditis following interleukin-2 and LAK cell therapy for metastatic renal cell carcinoma: correlation with tumor regression
- Author
-
Consuelo Corti, Silvia Heltai, Claudio Rugarli, Magda Marcatti, Carlo Besana, Marco Foppoli, Maria Grazia Sabbadini, and G. Di Lucca
- Subjects
Interleukin 2 ,endocrine system ,Cancer Research ,endocrine system diseases ,medicine.medical_treatment ,Immunotherapy, Adoptive ,Thyroiditis ,030218 nuclear medicine & medical imaging ,Autoimmune thyroiditis ,03 medical and health sciences ,0302 clinical medicine ,Renal cell carcinoma ,Carcinoma ,Medicine ,Humans ,Neoplasm Metastasis ,Killer Cells, Lymphokine-Activated ,Carcinoma, Renal Cell ,Lymphokine-activated killer cell ,business.industry ,Thyroid ,Histocompatibility Antigens Class II ,Thyroiditis, Autoimmune ,General Medicine ,Immunotherapy ,medicine.disease ,Kidney Neoplasms ,Recombinant Proteins ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Immunology ,Cancer research ,Interleukin-2 ,business ,medicine.drug - Abstract
A 63-year-old woman receiving recombinant interleukin-2 (rlL-2) + lymphokine activated killer cells for metastatic renal cell carcinoma developed autoimmune thyroiditis with clinical hypothyroidism and high titer anti-thyroglobulin and anti-microsomal antibodies. The onset of thyroid dysfunction was associated with tumor regression and resulted in complete response at the end of the treatment. Cytologic and cytofluorimetric studies on thyroid tissue showed two distinct populations, mainly consisting of small lymphocytes and large thyrocytes, and the latter expressed MHC class II antigens. After completion of rlL-2 treatment, hypothyroidism gradually decreased until resolution; complete tumor remission lasted 18 months. Mechanisms underlying the association between autoimmune thyroiditis and cancer regression are discussed.
- Published
- 1991